Tolland Development Company

Tolland Development Company is a biotechnology firm focused on the advancement of Transimmunization, a physiological immunotherapy platform derived from extracorporeal photopheresis (ECP). Founded by Dr. Richard Edelson, the pioneer of ECP and former Director of the Yale Cancer Center, the company holds critical intellectual property for the ex vivo activation of the immune system. The technology involves the controlled maturation of monocytes into dendritic cells, which are then used to program a patient's T-cells to recognize and attack specific disease targets. This approach is primarily applied to the treatment of cutaneous T-cell lymphoma, the prevention of organ transplant rejection, and the management of various autoimmune disorders. Tolland Development Company serves as a foundational entity for licensing and clinical development of these next-generation cellular therapies.